BARINTHUS BIOTHERAPEUT

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

12 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

12 May 2023 07:00:57 By Nasdaq GlobeNewswire

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

17 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

28 Mar 2023 07:00:11 By Nasdaq GlobeNewswire

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

24 Mar 2023 07:06:29 By Nasdaq GlobeNewswire

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

20 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

30 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

21 Nov 2022 09:31:34 By Nasdaq GlobeNewswire

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

10 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming November Investors Conferences

09 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

02 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients

31 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

27 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

03 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Vaccitech Promotes Gemma Brown as Chief Financial Officer

20 Sep 2022 15:30:00 By Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming September Investors Conferences

07 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

09 Aug 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

07 Jul 2022 15:15:00 By Nasdaq GlobeNewswire

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

22 Jun 2022 05:00:00 By Nasdaq GlobeNewswire